Testicular Volume Preservation is a proactive clinical strategy aimed at maintaining the physical size and structural integrity of the testes, primarily during periods of pharmacological suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Testicular atrophy is a common side effect of exogenous testosterone administration due to the suppression of pituitary gonadotropins. This preservation is often pursued to safeguard fertility potential and maintain the aesthetic and functional integrity of the gonads.
Origin
This term is a practical clinical descriptor within andrology, directly addressing the anatomical and functional consequences of central HPG axis suppression. The strategy arose from the need to mitigate the side effects of Testosterone Replacement Therapy (TRT) for men who desire to maintain testicular size or future fertility. It reflects a nuanced approach to hormonal optimization.
Mechanism
The primary mechanism involves the concurrent administration of an exogenous Luteinizing Hormone (LH) agonist, typically human Chorionic Gonadotropin (hCG), alongside the suppressive agent. The hCG directly binds to and stimulates the LH receptors on the testicular Leydig cells. This direct stimulation maintains the steroidogenic function and prevents the cellular atrophy of the seminiferous tubules that would otherwise occur from the prolonged absence of endogenous pituitary gonadotropin signaling.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.